Clinical trial
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has…
NCT00389701 · Sparrow Regional Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00389701 |
|---|---|
| Title | Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment |
| Official title | Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy |
| Lead sponsor | Sparrow Regional Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | bortezomib, dexamethasone |
| Enrollment | 30 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2009 |
| First posted | Oct 19, 2006 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: